歐康維視生物-B(01477.HK)公佈年度業績 研發開支大增257% 蘇州年設計產能達4.55億劑
格隆匯3月19日丨歐康維視生物-B(01477.HK)發佈公吿,截至2020年12月31日止年度,公司收益1309.6萬元人民幣,上年同期為19萬元;公司擁有人應占虧損22.65億元,上年同期虧損13.12億元;每股虧損7元。
虧損乃來自有關公司首次公開發售前優先股(其後已於上市時轉換為股份)的一次性、非現金國際財務報吿準則公平值調整虧損人民幣16.945億元;及以股份為基礎的付款開支人民幣2.94億元。
截至2020年12月31日止年度,公司的研發開支及資本化開發成本為人民幣3.55億元,較截至2019年12月31日止年度的人民幣9950萬元增加257%。開支乃主要來自OT-401的真實世界研究、候選藥物多項關鍵性III期臨牀試驗(包括OT-401、OT-101、OT-702、OT-1001及OT-301)及公司其他候選藥物的研究需要增加。
於報吿期內,公司產品管線已擴充至17個藥物資產,全面覆蓋眼前部及眼後部疾病。公司迄今共啟動6項III期臨牀試驗,與上市時僅有1項相比,新增了5項相關候選藥物啟動III期臨牀試驗。我們的候選藥物覆蓋葡萄膜炎、小兒近視、結膜炎、青光眼、濕性老年黃斑病變等諸多眼科用藥急需領域。公司在III期臨牀試驗的重大進展使公司成在中國眼科創新藥領域佔據領先地位,是目前在CDE登記進行III期臨牀試驗的創新眼科藥物數量最多的企業。
於報吿期內,海南省藥監局將公司的核心產品兼主要候選藥物之一OT-401(氟輕鬆玻璃體內植入劑)列為藥品真實世界研究試點名單,成為首批獲納入真實世界研究試點的藥物之一,OT-401的商業化進程有望提前。
報吿期內,公司積極推進OT-401、酒石酸溴莫尼定滴眼液、歐沁及康姝,實現總銷售收入人民幣1310萬元,同比增長6,792.6%,年內毛利率為86.8%。2021年1月單月銷售金額已近人民幣500萬元(未經審計),自公司首類藥物商業化以來,季度環比複合增長率約215.5%。
截至2020年12月31日,公司銷售及營銷團隊有69名僱員,已覆蓋全國267家醫院,其中覆蓋三級醫院53家。公司已初步建立了一支經驗豐富、覆蓋全國眼科市場的專業推廣團隊,進一步協助公司商業化產品,快速入院放量。
此外,截至本公吿日期,公司在蘇州生產場所的工程已接近完成,其年設計產能達4.55億劑,預計於2021年9月開始試生產,有望進一步降低產品成本,提高銷售利潤率。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.